Loading clinical trials...
Loading clinical trials...
A Phase III Open Label, Multicenter, Extension Study to Assess the Safety and Efficacy of Recombinant Coagulation Factor VIII (rVIII-SingleChain, CSL627) in Subjects With Severe Hemophilia A
Conditions
Interventions
rVIII-SingleChain
Locations
64
United States
Study Site 8400213
San Diego, California, United States
Study Site 8400241
Aurora, Colorado, United States
Study Site 8400118
Hartford, Connecticut, United States
Study Site 8400116
Miami, Florida, United States
Study Site 8400184
Chicago, Illinois, United States
Study Site 8400204
New Orleans, Louisiana, United States
Start Date
October 13, 2014
Primary Completion Date
January 19, 2021
Completion Date
January 19, 2021
Last Updated
October 27, 2021
NCT06820515
NCT07226206
NCT05987449
NCT04563520
NCT04645199
NCT06833983
Lead Sponsor
CSL Behring
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions